Our findings advance the understanding of the molecular signatures of PIS but also pave the way for the development of targeted therapies aimed at modulating the sphingolipid metabolic pathway and MIF signaling, thus offering new avenues for improving clinical management and patient outcomes in sepsis. This evidence concerns the gene MIF and Sepsis.